JDD Highlights
The June issue of the Journal of Drugs in Dermatology is available now. This month, we focus on Acne and Rosacea, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.
Read the JDD Now
Acne, Rosacea, Public Health, Anti-Aging, Aesthetic, and Medical Dermatology
The June issue of the Journal of Drugs in Dermatology is available now. This month, we focus on Acne and Rosacea, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.
Article Highlights
- Guest Editor Dr. James Q. Del Rosso stresses that even the best case scenario of teledermatology can never offer the same as a live in-person visit in Virtual Exams No Substitute for In-Person Care of Acne and Rosacea.
- Treating Inflammation in Rosacea: Current Options and Unmet Needs, authors discuss the underlying inflammatory nature of rosacea, treatments that target these inflammatory processes, and shortcomings of current therapies.
- An expert panel of pediatric dermatologists and dermatologists provide information on differential diagnosis, prevention, treatment, and maintenance in Consensus on Neonatal Through Preadolescent Acne.
- Tazarotene 0.045% lotion was efficacious and well tolerated in New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
-
Authors discuss a promising therapeutic option for improving scar appearance following surgery for NMSCs in Improving the Appearance of Surgical Facial Scars With IncobotulinumtoxinA and Microneedling.
Editor's Picks
You May Also Like
Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%
Acne Treatment Without the Dry-Out: Clascoterone Cream 1% Proves Gentle on the Skin Barrier Topical acne meds often come with an unfortunate side effect: dry, irritated skin that leaves patients…
The State of the Clinical Management Union: A Cross-Sectional Survey of Persons With Hidradenitis Suppurativa
April Issue Must-Read! Hidradenitis suppurativa (HS) isn’t just painful—it’s deeply isolating. And new data reveals why: the majority of people living with HS don’t feel heard, treated, or informed. In a…
